Feng Huapeng, Nakatsu Sumiho, Lopes Tiago Jose da Silva, Imai Masaki, Yamayoshi Seiya, Yamashita Makoto, Watanabe Tokiko, Kawaoka Yoshihiro
Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.
Vaccines (Basel). 2020 May 10;8(2):215. doi: 10.3390/vaccines8020215.
Ebola virus disease is a severe disease, often fatal, with a mortality rate of up to 90%. Presently, effective treatment and safe prevention options for Ebola virus disease are not available. Therefore, there is an urgent need to develop control measures to prevent or limit future Ebola virus outbreaks. Ebola virus protein-based virus-like particle (VLP) and inactivated whole virion vaccines have demonstrated efficacy in animal models, and the addition of appropriate adjuvants may provide additional benefits to these vaccines, including enhanced immune responses. In this study, we screened 24 compounds from injectable excipients approved for human use in Japan and identified six compounds that significantly enhanced the humoral response to Ebola VLP vaccine in a murine model. Our novel adjuvant candidates for Ebola VLP vaccine have already been demonstrated to be safe when administered intramuscularly or subcutaneously, and therefore, they are closer to clinical trials than adjuvants whose safety profiles are unknown.
埃博拉病毒病是一种严重疾病，通常致命，死亡率高达90%。目前，尚无针对埃博拉病毒病的有效治疗方法和安全预防措施。因此，迫切需要制定控制措施以预防或限制未来埃博拉病毒的爆发。基于埃博拉病毒蛋白的病毒样颗粒（VLP）和灭活全病毒疫苗已在动物模型中显示出疗效，添加合适的佐剂可能会为这些疫苗带来额外益处，包括增强免疫反应。在本研究中，我们从日本批准用于人类的注射用辅料中筛选了24种化合物，并鉴定出六种在小鼠模型中能显著增强对埃博拉VLP疫苗体液反应的化合物。我们用于埃博拉VLP疫苗的新型佐剂候选物已证明经肌肉注射或皮下注射给药时是安全的，因此，与安全性未知的佐剂相比，它们更接近临床试验阶段。
